ArticleJournal, genetic engineering & biotechnology2025
Prognostic and functional role of PPAR-alpha and SNP receptor (Leu162Val) in acute coronary syndrome: a potential novel target.
Article in Journal, genetic engineering & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivePPAR-alpha plays a key role in acute coronary syndrome (ACS). Its activation influences lipid metabolism and inflammation, impacting cardiovascular health and potentially mitigating risks related to heart conditions. This study aims to find the relationship between PPAR-alpha concentration and genetic polymorphism in ACS patients. METHODS AND MATERIALS: The study enrolled 90 ACS patients and 90 controls aged 30-70. Blood samples were analyzed for biomarkers (troponin, CK-MB, hs-CRP, PPARα) and rs1800206 SNP via ELISA and HRM-PCR. Data were statistically analyzed using SPSS v21, ANOVA, and ROC tests.
resultsThe results showed an increase in the levels of troponin, CK-MB, and hs-CRP for the patient groups compared to the healthy groups with significant differences between the groups (p-value <0.05). The level of (PPAR-alpha) was low in patients (1472.2 ± 74.5) and high in the healthy group (2051.8 ± 149.9) with significant differences between study groups. ROC analysis identified CK-MB, and hs-CRP as optimal biomarkers for ACS diagnosis; PPARα showed good predictive value. The study also found that the dominant genotype (CC) represented a small percentage of the patient samples while the homozygotes (CG) and the recessive (GG) represented the highest percentage, unlike the healthy group. Also, Allele (C) has a low percentage in the patients' group while allele (G) has a high percentage with considering the G allele as a risk factor. In addition, the results showed an abnormal distribution of Hardy-Weinberg equilibrium indicating the presence of factors extraneous to the community that changed the genetic pattern. The results also showed that the dominant genetic model is the best expressive for the samples of the Iraqi community infected with ACS.
conclusionsThe present study demonstrated a relationship between the concentration of PPAR-alpha and the genetic polymorphism of Leu162Val (rs1800206) SNP and acute coronary syndrome with a decrease in the concentration of PPAR-alpha and the predominance of the recessive gene and the recessive allele in patients compared to healthy individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.